drugset / Trial / NCT01363089

Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine

NCT01363089

Phase 1 Completed 21 enrolled Egalet Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

This was an open label, two way crossover study in healthy male subjects. Two treatments were administered to each subject, one treatment per study period, in a randomized manner. Subjects remained resident in the Clinical Unit from the evening of Day 1 until the morning of Day 2 of each period and there was a washout period of at least 2 days between treatments. A post study medical examination was performed prior to discharge in Period 2. The objective of this study was to assess the effects of a single dose of intranasal oxymetazoline hydrochloride on the pharmacokinetics of intranasal ketorolac in healthy male subjects.

Timeline

Start
2007-01
Primary completion
2007-03
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Tromethamine Small molecule 30 mg Intranasal
Subject Oxymetazoline Other / unclassified Intranasal

Indications

No indication recorded.